Hydroxyurea may increase the activity of fluorouracil plus folinic acid in advanced gastrointestinal cancer: Phase II study

Cancer Investigation

Volumn 14, Issue 3, 1996, Pages 234-238

  Di Costanzo, Francesco ^a   El Taani, Hani ^a   Parriani, Damiano ^a   Tagliaventi, Maria ^a   Bartolucci, Roberta ^a   Valenti, Lanfranco ^a   Manzione, Luigi ^b   Madejewicz, Stefan ^c  

^a University Hospital   (Italy)

^b General Hospital   (Italy)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; HYDROXYUREA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG POTENTIATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MUCOSA INFLAMMATION; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

EID: 0029784402     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909609012145     Document Type: Article

References (27)

1. Piedbois P, Buyse M, Rustum Y, et al: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992.
2. O'Dwyer PJ, Paul AR, Walczak J, et al: Phase II of biochemical modulation of fluorouracil by low dose PALA in patients with colorectal cancer. J Clin Oncol 7:1497-1503, 1990.
3. Nordic Gastrointestinal Tumor Adjuvant Treatment Group: Superiority of sequential methotrexate, fluorouracil and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: A randomized trial. J Clin Oncol 7:1437-1446, 1989.
4. Walder S, Schwatrz EL, Goldman M, et al: Fluorouracil and recombinant alpha-2a-interferon: An active regimen against advanced colorectal carcinoma. J Clin Oncol 7:1769-1175, 1989.
5. Kemeny N, Israel K, Niedzwiecki D, et al: Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. J Clin Oncol 8:313-318, 1990.
6. Howell SB, Wung WE, Taetle R: Modulation of 5-fluorouracil toxicity by allopurinol in man. Cancer 48:1281-1289, 1981.
7. Kao AK, Muggia FM, Dubin N, et al: Evolution of a sequential 5-FU and hydroxyurea combination in advanced bowel cancer. Cancer Treat Rep 68:1383-1385, 1984.
8. Goldstein LJ, Galski H, Fojo A, et al: Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81:116-124, 1989.
9. Park J-G, Kramer BS, Lai S-L, et al: Chemosensitivity patterns and expression of human multidrug resistance - associated MDR1 gene by human gastric and colorectal carcinoma cell lines. J Natl Cancer Inst 82:193-198, 1990.
10. Pinedo HM, Peters GJ: 5-Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 6:1653-1664, 1988.
11. Goldstein LJ, Galski H, Fojo A, et al: Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81:116-124, 1989.
12. Moran RG, Keyomarsi K: Biochemical rationale for the synergism of 5FU and folinic acid. J Natl Cancer Inst Monogr 5:159-163, 1987.
13. Lokich IJ, Pitman SW, Skarin AJ: Combined 5-fluorouracil hydroxyurea therapy for gastrointestinal cancer. Oncology 292:825-828, 1975.
14. Spears CP, Hayes AA, Shahinian AH, et al: Deoxyuridylate effects on thymidylate synthase-5-fluorodeoxyuridylate-folate ternary complex formation. Biochem Pharmacol 38:2985-2993, 1989.
15. Christen RD, Shalinsky DR, Howell SB: Enhancement of the loss of multiple drug resistance by hydroxyurea. Semin Oncol 19:3 (Suppl 9):94-100, 1992.
16. Madajewicz S, Di Costanzo F, Fiore J, et al: Enhancement of weekly 5FU/folinic acid (FA) with hydroxyurea modulation (HU) for advanced cancer phase I. Proc Am Soc Clin Oncol 10:469, 1991.
17. Yokes EE, Ratain MJ, Janisch LJ, et al: A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naïve patients. Eur J Cancer 27:217-218, 1991.
18. Yokes EE, Vijayakumar S, Hoffman PC, et al: 5-Fluorouracil with oral leucovorin and hydroxyurea and concomitant radiotherapy for stage III non small cell lung cancer. Cancer 66:437-442, 1990.
19. Lerner HJ: Clinical experience using hydroxyurea, 5-fluorouracil in hepatic metastasis from adenocarcinoma of the colon. Proc Am Assoc Cancer Res ASCO 15:32, 1974.
20. Engstrom PF, Maclntyre JM, Schutt AJ, et al: Chemotherapy of large bowel carcinoma-fluorouracil (FU) + hydroxyurea (HU) vs methyl-CCNU, oncovin, fluorouracil, and streptozotocin (MOF-Strep). Am J Clin Oncol 8:358-361, 1985.
21. Liberati AM, Di Costanzo F, Buzzi F, et al: 5-Fluorouracil, vincristine and hydroxyurea combination chemotherapy in metastatic colorectal cancer. Tumori 69:485-487, 1983.
22. Gebbia V, Gebbia N, Russo A, et al: Hydroxyurea modulates 5-fluorouracil antineoplastic activity in advanced head and neck carcinoma pretreated with chemotherapy. Anticancer Drugs 3: 347-349, 1992.
23. Gebbia V, Valenza R, Testa A, et al: Weekly levo-folinic acid and 5-fluorouracil plus hydroxyurea in metastatic gastrointestinal adenocarcinomas. Am J Clin Oncol 17:685-689, 1996.
24. De Gramont A, Louvet C, Bennamoun M, et al: Dual modulation of 5-fluorouracil (5FU) with folinic acid (LV) and hydroxyurea (HU) in metastatic colorectal cancer. Proc Am Soc Clin Oncol 12:701, 1993.
25. Von Hoff DD, McGill J, Davidson K, et al: Hydroxyurea decreases tumorigenicity of cell in nude mice by exporting extrachromosomally located oncogenes. Proc Am Soc Clin Oncol 11:235, 1992.
26. Di Costanzo F, Malacarne P, Zironi S, et al: Preliminary report of high dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: A randomized trial of the Italian Oncology Group for Clinical Research. J Surg Oncol 2(Suppl):137-140, 1991.
27. Di Costanzo F, Bartolucci R, Piccinini L, et al: High dose folinic acid (FA) and 5FU alone or combined with hydroxyurea (HU) in advanced colorectal cancer (CRC): A randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). Proc Am Soc Clin Oncol 11:463, 1992.